Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The goal of this phase 2 clinical trial is to evaluate the efficacy of nivolumab in
combination with CapeOX in patients with FGFR2-positive/PD-L1-positive/HER2-negative
metastatic gastric cancer.